News

CURE

FDA Grants Designation to Investigational Drug for Head and Neck Cancer

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for ...
TipRanks on MSN

Corbus Pharmaceuticals Receives FDA Fast Track for CRB-701

An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On September 16, 2025, Corbus Pharmaceuticals announced that the FDA ...

Corbus higher as FDA issues another fast track tag for lead asset

Corbus Pharmaceuticals (NASDAQ:CRBP) traded ~10% higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted another Fast Track designation for the cancer drug developer’s lead asset, ...

Corbus Gets FDA Fast Track Designation for Cancer Drug

Corbus Pharmaceuticals received fast track designation from the FDA for CRB-701, a drug to be used in the treatment of head and neck squamous cell carcinoma, a kind of cancer. A continuing clinical ...

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

Shares of Corbus Pharmaceuticals rose after the company said the FDA gave its cancer drug fast-track designation for the treatment of head and neck squamous cell carcinoma. The stock rose 13% to ...